- Home
- FRAF vs PBYI Comparison
FRAF vs PBYI Comparison
Compare FRAF & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRAF
- PBYI
- Stock Information
- Founded
- FRAF 1906
- PBYI 2010
- Country
- FRAF United States
- PBYI United States
- Employees
- FRAF N/A
- PBYI N/A
- Industry
- FRAF Major Banks
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- FRAF Finance
- PBYI Health Care
- Exchange
- FRAF Nasdaq
- PBYI Nasdaq
- Market Cap
- FRAF 165.3M
- PBYI 145.3M
- IPO Year
- FRAF N/A
- PBYI N/A
- Fundamental
- Price
- FRAF $37.32
- PBYI $2.91
- Analyst Decision
- FRAF
- PBYI Strong Buy
- Analyst Count
- FRAF 0
- PBYI 1
- Target Price
- FRAF N/A
- PBYI $7.00
- AVG Volume (30 Days)
- FRAF 14.4K
- PBYI 289.1K
- Earning Date
- FRAF 01-28-2025
- PBYI 02-27-2025
- Dividend Yield
- FRAF 3.43%
- PBYI N/A
- EPS Growth
- FRAF N/A
- PBYI 492.79
- EPS
- FRAF 2.51
- PBYI 0.47
- Revenue
- FRAF $69,210,000.00
- PBYI $243,569,000.00
- Revenue This Year
- FRAF N/A
- PBYI N/A
- Revenue Next Year
- FRAF N/A
- PBYI N/A
- P/E Ratio
- FRAF $14.87
- PBYI $6.24
- Revenue Growth
- FRAF 5.24
- PBYI 6.30
- 52 Week Low
- FRAF $25.11
- PBYI $2.23
- 52 Week High
- FRAF $38.41
- PBYI $7.15
- Technical
- Relative Strength Index (RSI)
- FRAF 70.88
- PBYI 48.76
- Support Level
- FRAF $37.25
- PBYI $2.69
- Resistance Level
- FRAF $38.41
- PBYI $2.98
- Average True Range (ATR)
- FRAF 0.59
- PBYI 0.12
- MACD
- FRAF 0.01
- PBYI 0.01
- Stochastic Oscillator
- FRAF 72.75
- PBYI 58.11
About FRAF Franklin Financial Services Corporation
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.